Optiscan has been featured in The Age, Sydney Morning Herald and Brisbane Times following the announcement of its latest breakthrough in gastrointestinal (GI) imaging technology.

The article covers Optiscan’s newly launched pre-clinical GI study, which will assess the capabilities of its Gen2 confocal imaging system in diagnosing and monitoring GI diseases, including colorectal cancer. The study is being conducted in collaboration with the University Medical Center Mainz in Germany and is led by world-renowned gastroenterologist Professor Ralph Kiesslich.

At the heart of this research is Optiscan’s miniature digital microscopy probe, designed to fit within the biopsy channels of most standard endoscopes. This enables real-time, high-resolution imaging of cellular structures during procedures, reducing the need for traditional biopsies and offering immediate diagnostic insights.

Dr. Camile Farah, CEO of Optiscan, highlighted the significance of this development, stating: "GI diseases represent a significant global health challenge, affecting millions of lives each year. Early detection and precise intervention are critical, yet traditional diagnostic tools often fall short in providing timely and accurate insights.”

The article also explores Optiscan’s push into AI-driven imaging, with research collaborations aimed at integrating artificial intelligence to enhance diagnostic accuracy and improve clinical workflows.

Read The Age full article here.

Read the Sydney Morning Herald full article here.

Read the Brisbane Times full article here.